Does SBC pay a dividend and is it safe?

SBC Medical Group Holdings Incorporated (SBC) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / SBC / dividends

STLN (38) SRTA (34) AHCO (33) AUNA (45) ⌘ Pro Terminal →

SBC Medical Group Holdings Incorporated (SBC) Dividend Safety Gauge & 10-Year DRIP Compounder

$5.31 +0.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.33

SBC Medical Group Holdings Incorporated (SBC) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (73.3% gross margin, 63% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $542.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SBC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, SBC Medical Group Holdings Incorporated (NASDAQ: SBC) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $5.31 (+0.66% 1D, market cap $542.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, SBC ranks #62 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SBC compare to STLN and SRTA in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), SBC carries a Roarable B (72/100 RQD), trailing P/E of 11.5x, gross margin of 73.3%, and ROIC of 63.1%. By comparison, STLN (Starling Oncology Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $665.5M) and SRTA (Strata Critical Medical Inc. (Class A)) posts a E grade (34/100 RQD, P/E 10.2x, ROIC -7.1%, cap $392.8M). Among the 5-stock peer group, SRTA leads on earnings multiple (10.2x) while SBC leads on capital efficiency (63.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SBC?

▼

Per SBC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001930313), SBC Medical Group Holdings Incorporated generated $173.6M in revenue (-15.5% YoY), $51.0M in net income, and $23.3M in free cash flow against $380.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (73.3% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.33 (+0.36%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 13.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+6.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SBC)Realized 20D OHLCV Swing Band: ±11%

Deterministic 5-Pillar Attribution (72/100 Composite)

🔍 WHY SBC SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 13.4% FCF Margin ($23.3M FCF) & 73.3% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+16/20 pts (22% of score)

SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning12/20 pts (-8 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A-$5.32+2.6% Next Q

Q2 (-2Q)

Grade B+$5.46-4.6% Next Q

Q3 (-1Q)

Grade B+$5.21+1.9% Next Q

Current

Grade B$5.31+7% Hist 90D α

Trajectory: A- (80) → B (72)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the SBC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, SBC faces multiple-compression risk if 11.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 70.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.92) or 200D SMA ($3.92) invalidates the momentum regime and cuts Target Base ($5.64) toward Bear Floor ($4.35).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SBC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SBC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 72%NO 28%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in SBC & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on SBC and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SBC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +61.89%▲ ASCENDING CHANNEL

2026-11-03O $5.69H $5.69L $5.28C $5.31VOL 155.3K

RES: $6.00SUP: $2.99SMA50: $4.92SMA200: $3.92

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SBC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SBC Butterfly Map → + Track SBC →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

1.6%/yr Implied 5Y Growth

vs. -15.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SBC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SBC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SBC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SBC)

Health Care Rank #62 of 1015 ⚔️ STLN vs SBC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SBC vs. STLN, SRTA, AHCO, AUNA)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, SBC Medical Group Holdings Incorporated (SBC) ranks #62 by composite RQD confidence (72/100, grade B) and #427 by equity capitalization ($542.5M). Within this direct 5-issuer industry benchmark cohort, SRTA leads on earnings valuation at 10.2x trailing P/E, while SBC leads on capital efficiency and profitability with 63.1% ROIC and 73.3% gross margin. SBC currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SBC ACTIVE SBC Medical Group Holdings Incorporated	B	72/100	11.5x	73.3%	63.1%	+0.66%	$542.5M	Benchmark Subject
STLN Starling Oncology Inc.	D-	38/100	—	—	-35.0%	-4.29%	$665.5M	/stln-vs-sbc →
SRTA Strata Critical Medical Inc. (Class A)	E	34/100	10.2x	20.9%	-7.1%	-3.60%	$392.8M	/srta-vs-sbc →
AHCO AdaptHealth Corp.	E	33/100	—	18.8%	2.2%	+1.72%	$792.2M	/ahco-vs-sbc →
AUNA Auna SA (Class A)	D	45/100	—	—	—	-0.22%	$333.8M	/auna-vs-sbc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001930313 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SBC Medical Group Holdings Incorporated (SBC) reported GAAP revenue of $173.6M (-15.5% vs. FY2024 revenue of $205.4M , and -10.3% cumulative change since FY2023) , GAAP net income of $51.0M, operating cash flow of $24.7M, and free cash flow of $23.3M (+29.1% YoY). On the balance sheet, SBC closed FY2025 with $380.4M in total assets against $0 in total debt (Altman Z-Score: 5.46, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$173.6M	$51.0M	$24.7M	$23.3M	$380.4M	—
FY2024 (FY)	2024-12-31	$205.4M	$46.6M	$20.6M	$18.0M	$266.1M	—
FY2023 (FY)	2023-12-31	$193.5M	$39.4M	$50.7M	$50.7M	—	—

3. SBC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SBC compare to STLN and SRTA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SBC?

Where is SBC trading relative to its 50-day, 200-day, and 52-week technical levels?

SBC last traded at $5.31 (+0.66% on volume of 276,490 shares), positioning the stock +7.93% above its 50-day simple moving average ($4.92) and +35.46% above its 200-day simple moving average ($3.92). Across its 52-week range of $2.78 to $5.79, SBC sits at the 84.1% percentile with a 14-day RSI of 50.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($4.73 to $5.89).

Direct Sub-Reports: SBC RQD Cockpit SBC 12M Forecast SBC Earnings & Move SBC Dividends & DRIP SBC Insiders & 13F SBC Whale Options SBC Profit Sankey SBC News & Why

ROARABLE RATING BRIEF • RQD 72/100 (B) ✓ SEC XBRL & RQD VERIFIED

SBC — SBC Medical Group Holdings Incorporated: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

SBC Medical Group Holdings Incorporated (SBC) earns a live Roarable RQD composite score of 72/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $5.31 (+0.66% 1D, market capitalization $542.5M).

Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 63.1%, gross margin of 73.3%, operating margin of 38.9%, and free cash flow yield of 3.98%.
Whale 13F & Options Flow (12/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (15/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of 5.46, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

SBC Medical Group Holdings Incorporated is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Nursing Services industry. Its market capitalization is $0.6B. Per the Market Data section, its gross margin is 73.3%, operating margin 38.9%, and net margin 29.4%. — for products, customers, or the specific revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SBC Medical Group Holdings Incorporated (SBC) reported $173.6M in annual revenue (up from $205.4M in FY2024, -15.5% YoY) and $51.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($193.5M revenue, $39.4M net income) through FY2025, SBC scaled operating cash flow to $24.7M and free cash flow to $23.3M, backed by $380.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B • RQD 72/100): Strong cash generator (73.3% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $2.78 – $5.79 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 11.5x trailing P/E and 6.1x EV/EBITDA against 38.9% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Nursing Services (Health Care), SBC carries a macro regime beta of 1.00 and gross margin of 73.3%.

Key Question #1: Can SBC sustain or expand its 38.9% operating margin and 63.1% ROIC against Medical/Nursing Services peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $173.6M and free cash flow of $23.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is SBC's 10.7x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SBC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SBC Medical Group Holdings Incorporated (SBC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SBC Debate Forum (3) ↓

🟢 CATALYST Benzinga • 1d ago

SBC Medical Invests ~$3.8M In AtomicSoftware’s Series C Funding Round

Companies to co-develop AI features, starting with physician documentation support, to enhance medicalforce and SBC Medical’s in-house systems and drive per-clinic productivity and profitabilitySBC Medical Group

Read Full Source ↗

🟡 MARKET WIRE SeekingAlpha • 6d ago

SBC Medical Group Holdings Incorporated (SBC) Presents at Cantor Fitzgerald Hong Kong's Inaugural Asia Longevity Forum - Slideshow

2026-10-27. The following slide deck was published by SBC Medical Group Holdings Incorporated in conjunction with this event.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 12d ago

SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age

IRVINE, Calif., October 22, 2026--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("The Company" or "SBC Medical"), a Medical Services Organization (MSO) providing management support across a wide range of healthca

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 12d ago

SBC Medical Group Commences In-House Development Of Test To Forecast Individual’s Biological Age Using DNA Methylation Analysis

SBC Medical Group Holdings Incorporated (NASDAQ:SBC) ("The Company" or "SBC Medical"), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 22d ago

SBC Medical to Present at Cantor Fitzgerald Hong Kong’s Inaugural Asia Longevity Forum

Yuya Yoshida, Director, CFO and COO, to Present at the Forum in Hong Kong on October 26 and Hold One-on-One Investor Meetings on October 27; Non-Deal Roadshow to Follow on October 28IRVINE, Calif., Oct. 12, 2026 (GLOBE N

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

SBC Medical Forms Capital and Business Alliance with AtomicSoftware, Provider of the medicalforce Clinic Management Platform Used by 800+ Clinics in Japan

IRVINE, Calif., November 02, 2026--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("The Company" or "SBC Medical"), a Medical Services Organization (MSO) providing management support across a wide range of healthc

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 39d ago

SBC Medical to Participate in Several Upcoming Investor Conferences in October 2026

IRVINE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 65d ago

SBC Medical Group Re-Accelerates Growth as EBITDA Surges 32% in Q2

SBC Medical Group (NASDAQ:SBC) said its growth re-accelerated in the second quarter of 2026 following structural reforms undertaken in 2025, with profit growth exceeding revenue growth as the company expanded management

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SBC Bull vs. Bear Conversation Board — What's Your Call at $5.31?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SBC 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $6.71 (+27.1%)

📌 Pinned Debate

Return on invested capital of 63.1% with a P/E TTM of 11.5 and EV/EBITDA of 6.1 signals strong capital efficiency at a modest valuation

Return on invested capital of 63.1% with a P/E TTM of 11.5 and EV/EBITDA of 6.1 signals strong capital efficiency at a modest valuation.. When you look under the hood at SBC, Fundamental Cash Engine is 16/20 with 73.3% gross margins and 63.1% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (12/20) has been quietly accumulating below $5.79. My 12M target is $6.71.

EarningsSniper 🐂 BULL

Both sides have a point here — SBC's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $4.07 (-22.9%)

Spot @ $5.28

Revenue fell from $205.4M in FY 2024 to $173.6M in FY 2025 and the shares sit near the top of a $2.78 to $5.79 52-week range.

Careful chasing SBC at $5.28. Revenue fell from $205.4M in FY 2024 to $173.6M in FY 2025 and the shares sit near the top of a $2.78 to $5.79 52-week range.. Gross margin is 73.3%, but operating margin is 38.9%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $4.07 on multiple compression.